Medicine
Anthim 600 mg/6 mL injection
Anthim 600 mg/6 mL injection is a prescription medicine containing Obiltoxaximab for intravenous use, marketed by Elusys Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to…
Key facts
- Active ingredient (INN)
- Obiltoxaximab
- Brand
- Anthim
- Strength
- 600 mg/6 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 6 mL
- Marketing authorisation holder
- Elusys Therapeutics
- Manufacturer
- Elusys Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store in refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do Not Freeze. Do Not Shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J06BB22 Obiltoxaximab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 March 2016
- Identifiers
- RxCUI 1746910, 1746915DailyMed set ID 39ad8799-00a4-4fc8-9852-c0536350c474NDC 69604-204Application BLA125509
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 6 mL in 1 vial, single-use | 69604-204-02 | Elusys Therapeutics | 18 March 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Obiltoxaximab is an anthrax protective antigen-directed antibody indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs, among other approved uses. MedsAcross supplies Obiltoxaximab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ObiltoxaximabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Anthim prescribing information (Elusys Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Anthim 600 mg/6 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.